Core Viewpoint - Hanyu Pharmaceutical has signed a licensing agreement with Vitamedic Health for the exclusive commercialization of semaglutide in Brazil, marking a significant step in the company's international strategy in South America [1][3]. Group 1: Company Overview - Hanyu Pharmaceutical is a national high-tech enterprise focused on the research, production, and sales of innovative drugs, particularly in the peptide drug sector for over 20 years [2]. - The company has a comprehensive product pipeline covering major peptide targets globally and is the first to receive FDA approval for liraglutide ANDA in the U.S. [2]. - Hanyu has nearly 500 domestic and international patents authorized, with a product line that includes innovative drugs and generic formulations targeting GLP-1 receptors [2]. Group 2: Partnership Details - Vitamedic Health, the Brazilian partner, has over 40 years of industry experience and specializes in the generic drug sector, with a diverse sales network in Brazil [2]. - The collaboration will focus on product registration, market access, localization promotion, and long-term service [1][3]. Group 3: Market Potential - The market for semaglutide is substantial, with projected sales reaching $29.296 billion in 2024, making it one of the top-selling drugs alongside Merck's pembrolizumab [3]. - As patents for semaglutide expire starting in 2026, the generic market is expected to expand rapidly, increasing accessibility for a broader patient population [3]. - This partnership is expected to open up the Brazilian market, which has a population of over 200 million, and potentially expand into other South American and emerging markets [3]. Group 4: Leadership Statements - Hanyu's Chairman expressed optimism about the partnership, highlighting Brazil's role as a key pharmaceutical market in Latin America and the strengths of Vitamedic Health in market operations [4]. - Vitamedic Health's General Manager emphasized the growing local demand for semaglutide and the quality of Hanyu's products, which have passed multiple international certifications [4].
翰宇药业:司美格鲁肽达成巴西对外授权协议,海外布局再迈关键一步